The long-term efficacy and safety data significantly derisk TransCon PTH and support its commercial potential in hypoparathyroidism. Monitor upcoming quarterly reports for revenue growth from Yorvipath (palopegteriparatide) sales, as this data should aid physician adoption.
ASND drugs
ASND drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 15 $223.29entry
- T+1 · 5mo ago +3.54%α +4.14% · $231.20
- T+5 · 5mo ago +2.11%α +3.49% · $228.00
- T+20 · 4mo ago +18.78%α +19.53% · $265.22
- T+60 · 2mo ago +16.80%α +15.80% · $260.81
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Ascendis Pharma reported Week 182 data from the Phase 3 PaTHway Trial for TransCon PTH (palopegteriparatide) in hypoparathyroidism, showing sustained efficacy and safety over 3.5 years. Key results include 86% responders, 100% independence from active vitamin D, 96% independence from therapeutic calcium, normalized kidney function, and no anti-PTH antibodies. The data reinforce the drug's long-term value proposition.
Key Facts
- 86% of patients met the multi-component responder endpoint (normal serum calcium, no active vitamin D, ≤600 mg/day calcium).
- 100% of patients achieved independence from active vitamin D.
- 96% of patients achieved independence from therapeutic doses of calcium (<600 mg/day).
- Mean eGFR increased by 11.0 mL/min/1.73m² from baseline and was maintained through Week 182, contrasting with age-related decline.
- Mean 24-hour urine calcium normalized within 26 weeks and remained normal.
- No patients developed anti-PTH antibodies during 3.5 years of treatment.
- No new safety signals; no discontinuations related to study drug.
Financial Impact
No financial data provided; the filing contains clinical trial results only.
Risk Factors
- Commercial adoption may be slower than expected due to competition or payer dynamics.
- Regulatory updates or label changes could impact market access.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001193125-26-270227 |
| Document: 0001193125-26-270227-index-headers.html | 0001193125-26-270227 |
| Document: 0001193125-26-270227-index.html | 0001193125-26-270227 |
| Document: 0001193125-26-270227.txt | 0001193125-26-270227 |
Track record
41 reports on ASND
13 of 18 bullish or bearish reports moved the stock their way by T+60. Best: +26.62% at T+20 after the Jun 2, 2026 report. 24 of 26 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $271.96 Now $271.73 −0.08% settles Feb 12
- Nov 12, 20264d ago 6-K Neutral 2/10 Entry $275.39 Now $271.73 −1.33% settles Feb 11
- Nov 12, 20264d ago 6-K Bullish 6/10 Entry $267.07 Now $271.73 +1.74% settles Feb 10
- Nov 12, 20264d ago Press Release Neutral 5/10 Entry $267.07 Now $271.73 +1.74% settles Feb 10
- Nov 6, 202610d ago 6-K Bullish 6/10 Entry $259.85 Now $271.73 +4.57% settles Feb 5
- Nov 6, 202610d ago Press Release Bullish 6/10 Entry $256.82 Now $271.73 +5.81% settles Feb 4
- Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $253.45 Now $271.73 +7.21% settles Feb 3
- Nov 2, 202614d ago Institutional Cluster Bullish 4/10 Entry $250.17 Now $271.73 +8.62% settles Feb 1
- Oct 26, 202621d ago 6-K Bullish 5/10 Entry $245.85 Now $271.73 +10.53% settles Jan 25
- Oct 16, 20264w ago 6-K Bullish 7/10 Entry $225.25 Now $271.73 +20.63% settles Jan 13
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers